Securities Code: 002294
Securities Abbreviation: Xinlitai
Announcement No.: 2026-052
Shenzhen Xinlitai Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of the information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions. Recently, Shenzhen Xinlitai Pharmaceutical Co., Ltd. received a notification from its subsidiary, Salubris Biotherapeutics, Inc. (hereinafter referred to as "Salubris Bio"), that it presented the latest clinical progress data of JK06 in the American Society of Clinical Oncology (ASCO) annual meeting. The data further indicates that JK06 demonstrates good safety and efficacy in patients with unresectable locally advanced or metastatic tumors, including non-small cell lung cancer (NSCLC) and breast cancer. The relevant information is announced as follows:
I. Progress of JK06 Clinical Trials
The latest clinical data of JK06 from the ASCO meeting covers 173 patients with advanced recurrent/refractory solid tumors enrolled in Europe (in some countries) (data as of May 12, 2026). Among them, there are 42 patients in the dose escalation cohort and 131 patients in the dose expansion cohort (including 64 NSCLC patients, 44 breast cancer patients, and a basket cohort of 23 patients with various tumor types known to express 5T4). These patients received JK06 treatment every three weeks (Q3W), and the efficacy evaluation criteria were based on RECIST 1.1.